NEO Neogenomics Inc

Price (delayed)

$45.71

Market cap

$5.39B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$5.36B

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
The quick ratio has soared by 143% from the previous quarter
The equity has soared by 67% year-on-year and by 22% since the previous quarter
NEO's debt has soared by 167% QoQ
The gross margin has contracted by 15% YoY and by 4.5% from the previous quarter

Key stats

What are the main financial stats of NEO
Market
Shares outstanding
117.93M
Market cap
$5.39B
Enterprise value
$5.36B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.34
Price to sales (P/S)
11.7
EV/EBIT
N/A
EV/EBITDA
264.87
EV/Sales
11.81
Earnings
Revenue
$453.95M
EBIT
-$21.93M
EBITDA
$20.25M
Free cash flow
-$29.62M
Per share
EPS
-$0.09
Free cash flow per share
-$0.25
Book value per share
$7.21
Revenue per share
$3.91
TBVPS
$10.03
Balance sheet
Total assets
$1.49B
Total liabilities
$650.7M
Debt
$584.7M
Equity
$843.71M
Working capital
$874.98M
Liquidity
Debt to equity
0.69
Current ratio
13.91
Quick ratio
13.37
Net debt/EBITDA
-1.35
Margins
EBITDA margin
4.5%
Gross margin
39.9%
Net margin
-2.4%
Operating margin
-5.2%
Efficiency
Return on assets
-1%
Return on equity
-1.5%
Return on invested capital
-3.3%
Return on capital employed
-1.5%
Return on sales
-4.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
2.03%
1 week
5.4%
1 month
1.83%
1 year
24.48%
YTD
-15.1%
QTD
1.2%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$453.95M
Gross profit
$181.1M
Operating income
-$23.81M
Net income
-$10.96M
Gross margin
39.9%
Net margin
-2.4%
The company's operating income has shrunk by 70% QoQ
Neogenomics's operating margin has plunged by 68% from the previous quarter
The gross margin has contracted by 15% YoY and by 4.5% from the previous quarter
The revenue rose by 8% YoY and by 2.1% QoQ

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
P/E
N/A
P/B
6.34
P/S
11.7
EV/EBIT
N/A
EV/EBITDA
264.87
EV/Sales
11.81
The equity has soared by 67% year-on-year and by 22% since the previous quarter
The price to book (P/B) is 27% more than the 5-year quarterly average of 5.0 but 3.9% less than the last 4 quarters average of 6.6
The price to sales (P/S) is 102% higher than the 5-year quarterly average of 5.8 and 8% higher than the last 4 quarters average of 10.8
The revenue rose by 8% YoY and by 2.1% QoQ

Efficiency

How efficient is Neogenomics business performance
The company's return on sales has shrunk by 200% QoQ
NEO's ROIC has dropped by 136% since the previous quarter

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 130% greater than the total liabilities
Neogenomics's total liabilities has soared by 186% YoY and by 121% from the previous quarter
The quick ratio has soared by 143% from the previous quarter
NEO's debt is 31% lower than its equity
NEO's debt has soared by 167% QoQ
The debt to equity has surged by 130% year-on-year and by 116% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.